A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects

NCT02959060 | Completed Phase 1

• 1 other identifier: CV010-014
• Study Type: interventional
• Target: 16
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is to evaluate the effect of rifampin on the single-dose pharmacokinetics (PK) of BMS-986177 in healthy participants with parameters like Cmax, AUC(INF), AUC(0-T)

Conditions

Thrombosis

Outcome Measures

Primary Outcomes (3)

• Maximum observed plasma concentration (Cmax)

  Days1-15

• Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

  Days1-15

• Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

  Days1-15

Secondary Outcomes (1)

• Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death

  Screening- until 30 days after discontinuation of dosing or subject's participation

Study Arms (1)

BMS-986177 and Rifampin

EXPERIMENTAL

Drug: BMS-986177; Drug: Rifampin

Interventions

BMS-986177 DRUG

Single dose of BMS-986177 and multiple doses of Rifampin

BMS-986177 and Rifampin

Rifampin DRUG

Single dose of BMS-986177 and multiple doses of Rifampin

BMS-986177 and Rifampin

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signed Informed Consent
• Healthy men and women (not of child bearing potential) as determined by medical history, surgical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests including coagulation parameters.
• Subjects with body mass index of 18 to 30 kg/m2, inclusive and with normal kidney function.
• Women participants must have documented proof that they are not of childbearing potential.
• Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with BMS-986177 plus 5 half-lives (3 days) plus 90 days (duration of sperm turnover) for a total of 93 days after completion of BMS-986177 treatment.

You may not qualify if:

• Any significant acute or chronic medical illness, including any other condition listed as a contraindication in the rifampin package insert
• History of recurrent headaches, dizziness, chronic diarrhea, gastroesophageal reflux disease, dyspepsia, gastrointestinal ulcer disease, recurrent urinary tract infections, hypermenorrhea and recurrent candida infections, abnormal bleeding, history of hemophilia, Rosenthal syndrome, FXIa deficiency, or other coagulopathies.
• Recent surgery, head injury, blood transfusion, systemic lupus erythamatous, aneurysm, drug or alcohol abuse and use of tobacco or nicotine containing products in past six months.
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs, or clinical laboratory determinations beyond what is consistent with the target population
• History of allergy to BMS-986177, FXIa inhibitors , rifampin or related compounds

Sponsors & Collaborators

• Bristol-Myers Squibb: lead

Related Publications (1)

• Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Sci Rep. 2022 Dec 23;12(1):22239. doi: 10.1038/s41598-022-25936-2.

  PMID: 36564395 DERIVED

Related Links

• BMS Clinical Trial Education Resource
• FDA Safety Alerts and Recalls
• Investigator Inquiry Form

MeSH Terms

Conditions

Thrombosis

Interventions

milvexian; Rifampin

Condition Hierarchy (Ancestors)

Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Rifamycins; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Study Officials

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2016
• First Posted: November 8, 2016
• Study Start: November 1, 2016
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: January 6, 2017

Record last verified: 2017-01